Меню
Идёт набор NCT05793502

Study on Effectiveness and Safety of LBBaP With Solia S and Selectra 3D Developed by BIOTRONIK

Наблюдательное Consented to Participate in the Trial and Signed an ICF Patients With an Indication for PM Implantation or CRTP

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Solia S and Selectra 3D Developed by BIOTRONIK.
Кому может быть актуально
Состояния в реестре: Consented to Participate in the Trial and Signed an ICF, Patients With an Indication for PM Implantation or CRTP. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Китай
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Обзор

This study is aimed to assess the effectiveness and safety of LBBaP with Solia S and Selectra 3D in the Chinese population by analyzing the operation success rate and the system stability during follow-up visits.

Подробное описание

Traditional ventricular pacing leads are placed in and around the right ventricular apex (RVA), which are easy to operate. The long-term safety and efficacy of right ventricular pacing (RVP) in the treatment of bradycardia arrhythmia have been demonstrated. However, it is shown by CTOPP (Canadian Trial of Physiologic Pacing) study (1), MOST (Micro-Optical Sectioning Tomography) study (2) and UKPACE (United Kingdom Pacing and Cardiovascular Events) study (3) that long-term and high-proportion right ventricular apical pacing (RVAP) may lead to ventricular systolic asynchrony, and accordingly increase the risks of cardiac failure (cardiac insufficiency) and atrial fibrillation (AF).

The concept of His bundle pacing (HBP) has been put forward for a long time, in which His bundle is directly stimulated to synchronously excite the ventricles mainly through the conduction of the His-Purkinje system (HPS) in the electrical activity of the heart. The study performed by Vijayaman et al. (4) shows that HBP can reduce the long-term mortality and the risks of hospitalization for cardiac failure and upgrading to CRT compared with the traditional RVAP. However, HBP surgery has the following disadvantages: (1) It is rather difficult to fix the leads, the operation duration is long, the suture removal duration is long, and the learning curve of doctors is long; (2) The threshold value is high during implantation and may further increase in the long term, and the sensory power is rather low. Therefore, the implantation of spare leads is recommended in relevant guidelines, increasing the hardware burden in patients; (3) The implantation site of patients with conduction block below His bundle is rather difficult or unable to cross the block site.

In order to improve the HBP surgery, Chinese doctors have put forward LBBaP in recent years, arousing widespread concern all over the world. Dedicated sheath tubes and electrode leads are adopted in the technique. Specifically, electrode leads are "screwed" into the left bundle branch area under the left ventricular intima from the right ventricular septum (RVS), and the left bundle branch pacing (LBBP) is performed to improve bradycardia. Compared with HBP, LBBP has the following advantages: (1) As the implantation site is easier to locate, the operation difficulty is reduced; (2) With a lower and more stable threshold, the sensitivity is better; (3) Distal block is corrected; (4) An enough space is left for atrioventricular junction ablation.

At present, it is collectively known as HBP in the international community. LBBaP refers to conduction system pacing, the performing of which depends on dedicated tools or instruments. In early times, the positioning and fixation of shaping steel wires in combination with active-fixation leads adopted in the technique were realized with the aid of a mapping catheter. The operation success rate of HBP was rather low and LBBaP could not be realized. With the introduction of dedicated sheath tubes by various manufacturers, the operation success rate has been greatly improved. However, there are no enough data derived from large-scale studies at home and abroad on the effectiveness and safety of LBBaP with Selectra 3D and Solia S developed by BIOTRONIK at present.

This study is aimed to assess the effectiveness and safety of LBBaP with Solia S and Selectra 3D in the Chinese population by analyzing the operation success rate and the system stability during follow-up visits.

Вмешательства

  • Устройство Solia S and Selectra 3D Developed by BIOTRONIK
    LBBaP with Solia S and Selectra 3D Developed by BIOTRONIK

Первичные конечные точки

  • Implantation success rate of LBBaP [Срок оценки: During the surgery]
  • Intraoperatively, the incidence of serious adverse events for devices associated with Solia S and Selectra 3D implantation rate [Срок оценки: During the surgery]
  • Occurrence of serious adverse events rate [Срок оценки: From the time of surgery to the 12-month post-implantation visit]
Вторичные конечные точки (4)
  • Number of participants with abnormal pacing parameters and abnormal ECG readings [Срок оценки: 1 month and 12 months post-procedure]
  • Changes of cardiac ultrasound values (including LVEF, LVESD and LVEDD) [Срок оценки: 12 months post-procedure.]
  • Changes of NYHA class [Срок оценки: 1 month and 12 months post-procedure]
  • Changes of EQ-5D-5L assessment [Срок оценки: 1 month and 12 months post-procedure]

Критерии участия

Критерии включения

  • All patients for whom it is the first time to receive permanent pacemaker implantation or CRT, and on whom LBBaP will be performed for trial.
  • Willingness to participate in the investigation and sign the ICF
  • Ability and willingness to perform all follow-up visits at the investigation sites

Критерии исключения

  • Age less than 18 years
  • Patients with cardiac amyloidosis
  • Patients with ventricular hypertrophy (interventricular septum diastolic thickness measured from two-dimensional echocardiography: ≥ 15 mm; or, interventricular septum diastolic thickness for patients with a definite family history: ≥ 13 mm)
  • Participating in other intervention clinical trials
  • Life-expectancy less than one year
  • Pregnancy and/or breast feeding

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Модель наблюдения
Только случаи

Центры проведения

Китай · 1 центр
  • Shanxi Cardiovascular Hospital — Taiyuan

Идентификаторы

NCT: NCT05793502 · 20230320

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗